The advent of cystic fibrosis transmembrane conductance regulator (CFTR) therapy has significantly increased the life expectancy for individuals with cystic fibrosis (CF).
As a result, adults with CF are more likely to have families than they have in the past.
Although the overall pregnancy rate among women with CF age 18-44 is declining (mirroring trends in the general population), the overall number of pregnancies is increasing due to the increasing number of adults with CF. However, little is known about CFTR modulator use in pregnant or breastfeeding mothers, as outlined in a recent review of CF-therapies in pregnant and breastfeeding women. Presently, there is one report of an uncomplicated pregnancy during ivacaftor use, and one case of a successful pregnancy in a woman who was maintained on lumacaftor/ivacaftor with reported maternal and fetal drug levels. In this study, we aim to study the pharmacokinetics of CFTR modulators in pregnancy as well as while breastfeeding.
This information will hopefully improve counseling while offering them for CF patients given the tremendous improvements seen in non-pregnant adults.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female 18 years of age and older
Female who has a diagnosis of cystic fibrosis
Female who is taking cystic fibrosis transmembrane conductance regulator (CFTR) modulator medication during pregnancy and postpartum
You may not be if
Female \< 18 years of age
Female with cystic fibrosis who is not taking cystic fibrosis transmembrane conductance regulator (CFTR) modulator medication during pregnancy and postpartum
Participant has contraindication to breastfeeding or not planning to breastfeed